1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018;137(12):e67-e492. [
DOI:10.1161/CIR.0000000000000573]
2. Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013;2013:152786. [
DOI:10.1155/2013/152786] [
PMID] [
PMCID]
3. Lechner K, von Schacky C, McKenzie AL, Worm N, Nixdorff U, Lechner B, et al. Lifestyle factors and high-risk atherosclerosis: Pathways and mechanisms beyond traditional risk factors. Eur J Prev Cardiol. 2020;27(4):394-406. [
DOI:10.1177/2047487319869400] [
PMID] [
PMCID]
4. Tada H, Takamura M, Kawashiri MA. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb. 2019;26(7):583-591. [
DOI:10.5551/jat.RV17034] [
PMID] [
PMCID]
5. Mohammadi A, Balizadeh Karami AR, Dehghan Mashtani V, Sahraei T, Bandani Tarashoki Z, Khattavian E, et al. Evaluation of Oxidative Stress, Apoptosis, and Expression of MicroRNA-208a and MicroRNA-1 in Cardiovascular Patients. Reports of Biochemistry and Molecular Biology. 2021;10(2):183-196. [
DOI:10.52547/rbmb.10.2.183] [
PMID] [
PMCID]
6. Roodi NE, Osguei NK, Daloee MH, Pasdar A, Ghayour-Mobarhan M, Ferns G, et al. Association of endonuclease G gene variants with cardiovascular disease risk factors. Rep Biochem Mol Biol. 2019;8(2):147-152.
7. Lubrano V, Balzan S. Roles of LOX-1 in microvascular dysfunction. Microvasc Res. 2016;105:132-40. [
DOI:10.1016/j.mvr.2016.02.006] [
PMID]
8. Pant S, Deshmukh A, Gurumurthy GS, Pothineni NV, Watts TE, Romeo F, et al. Inflammation and atherosclerosis--revisited. J Cardiovasc Pharmacol Ther. 2014;19(2):170-8. [
DOI:10.1177/1074248413504994] [
PMID]
9. Kattoor AJ, Goel A, Mehta JL. LOX-1: Regulation, Signaling and Its Role in Atherosclerosis. Antioxidants (Basel). 2019;8(7):218. [
DOI:10.3390/antiox8070218] [
PMID] [
PMCID]
10. Pothineni NVK, Karathanasis SK, Ding Z, Arulandu A, Varughese KI, Mehta JL. LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation. J Am Coll Cardiol. 2017;69(22):2759-2768. [
DOI:10.1016/j.jacc.2017.04.010] [
PMID]
11. Chen Q, Reis SE, Kammerer C, Craig WY, LaPierre SE, Zimmer EL, et al. Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. Circulation. 2003;107(25):3146-51. [
DOI:10.1161/01.CIR.0000074207.85796.36] [
PMID]
12. Wang L, Yanuck D, Beecham A, Gardener H, Slifer S, Blanton SH, et al. A candidate gene study revealed sex-specific association between the OLR1 gene and carotid plaque. Stroke. 2011;42(3):588-92. [
DOI:10.1161/STROKEAHA.110.596841] [
PMID] [
PMCID]
13. Zhang J, Yin C, Zhang Y, Zhao L, Fu H, Feng J. The role of OLR1 polymorphisms in determining the risk and prognosis of ischemic stroke in a Chinese population. NeuroRehabilitation. 2013;32(2):391-6. [
DOI:10.3233/NRE-130860] [
PMID]
14. Morini E, Rizzacasa B, Pucci S, Polidoro C, Ferrè F, Caporossi D, et al. The human rs1050286 polymorphism alters LOX-1 expression through modifying miR-24 binding. J Cell Mol Med. 2016;20(1):181-7. [
DOI:10.1111/jcmm.12716] [
PMID] [
PMCID]
15. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. [
DOI:10.1093/eurheartj/ehv320] [
PMID]
16. Killip T, 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20(4):457-64. [
DOI:10.1016/0002-9149(67)90023-9]
17. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031-7. [
DOI:10.1161/01.CIR.102.17.2031] [
PMID]
18. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091. [
DOI:10.1136/bmj.38985.646481.55] [
PMID] [
PMCID]
19. Rupprecht HJ, Geeren M, Geeren M, Weilemann S, Schuster HP. [Acute coronary syndrome without ST-elevation (NSTE-ACS)]. Herz. 2019;44(1):10-5. [
DOI:10.1007/s00059-018-4776-1] [
PMID]
20. Maiolino G, Rossitto G, Caielli P, Bisogni V, Rossi GP, Calò LA. The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. Mediators Inflamm. 2013;2013:714653. [
DOI:10.1155/2013/714653] [
PMID] [
PMCID]
21. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg. 2008;70(3):193-219.
22. Huang H, Mai W, Liu D, Hao Y, Tao J, Dong Y. The oxidation ratio of LDL: a predictor for coronary artery disease. Dis Markers. 2008;24(6):341-9. [
DOI:10.1155/2008/371314] [
PMID] [
PMCID]
23. Napoleão P, Selas M, Toste A, Turkman A, Andreozzi V, Viegas-Crespo AM, et al. Serial changes in oxidized low-density lipoprotein associated with culprit vessel in ST-elevation myocardial infarction--a promising marker? Rev Port Cardiol. 2009;28(3):303-8.
24. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes. 2004;53(4):1068-73. [
DOI:10.2337/diabetes.53.4.1068] [
PMID]
25. Yamashita H, Ehara S, Yoshiyama M, Naruko T, Haze K, Shirai N, et al. Elevated plasma levels of oxidized low-density lipoprotein relate to the presence of angiographically detected complex and thrombotic coronary artery lesion morphology in patients with unstable angina. Circ J. 2007;71(5):681-7. [
DOI:10.1253/circj.71.681] [
PMID]
26. Goldstein JA, Chandra HR, O'Neill WW. Relation of number of complex coronary lesions to serum C-reactive protein levels and major adverse cardiovascular events at one year. Am J Cardiol. 2005;96(1):56-60.
https://doi.org/10.1016/j.amjcard.2005.02.044 [
DOI:10.1016/0002-9149(74)90093-9] [
PMID]
27. Fang R, Zhang N, Wang C, Zhao X, Liu L, Wang Y, et al. Relations between plasma ox-LDL and carotid plaque among Chinese Han ethnic group. Neurological Research. 2011;33(5):460-6. [
DOI:10.1179/016164111X13007856083927] [
PMID]
28. Kayo S, Ohsawa M, Ehara S, Naruko T, Ikura Y, Hai E, et al. Oxidized low-density lipoprotein levels circulating in plasma and deposited in the tissues: comparison between Helicobacter pylori-associated gastritis and acute myocardial infarction. Am Heart J. 2004;148(5):818-25. [
DOI:10.1016/j.ahj.2004.05.042] [
PMID]
29. Trifunović D, Stanković S, Marinković J, Banović M, Đukanović N, Vasović O, et al. Oxidized Low Density Lipoprotein and High Sensitive C-Reactive Protein in Non-Diabetic, Pre-Diabetic and Diabetic Patients in the Acute Phase of the First Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. J Med Biochem. 2015;34(2):160-169. [
DOI:10.2478/jomb-2014-0037] [
PMID] [
PMCID]
30. Tian K, Ogura S, Little PJ, Xu SW, Sawamura T. Targeting LOX-1 in atherosclerosis and vasculopathy: current knowledge and future perspectives. Ann N Y Acad Sci. 2019;1443(1):34-53. [
DOI:10.1111/nyas.13984] [
PMID]
31. Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F, et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res. 2007;100(11):1634-42. [
DOI:10.1161/CIRCRESAHA.107.149724] [
PMID]
32. Mango R, Clementi F, Borgiani P, Forleo GB, Federici M, Contino G, et al. Association of single nucleotide polymorphisms in the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. J Med Genet. 2003;40(12):933-6. [
DOI:10.1136/jmg.40.12.933] [
PMID] [
PMCID]
33. Knowles JW, Assimes TL, Boerwinkle E, Fortmann SP, Go A, Grove ML, et al. Failure to replicate an association of SNPs in the oxidized LDL receptor gene (OLR1) with CAD. BMC Medical Genetics. 2008;9:23. [
DOI:10.1186/1471-2350-9-23] [
PMID] [
PMCID]
34. Mango R, Biocca S, del Vecchio F, Clementi F, Sangiuolo F, Amati F, et al. In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction. Circ Res. 2005;97(2):152-8. [
DOI:10.1161/01.RES.0000174563.62625.8e] [
PMID]
35. Zhang Q, Chu Y, Jin G, Dai J, Kang H. Association Between LOX-1, LAL, and ACAT1 Gene Single Nucleotide Polymorphisms and Carotid Plaque in a Northern Chinese Population. Genet Test Mol Biomarkers. 2020;24(3):138-144. [
DOI:10.1089/gtmb.2019.0209] [
PMID]
36. Chen Q, Reis SE, Kammerer C, Craig W, McNamara DM, Holubkov R, et al. Association of anti-oxidized LDL and candidate genes with severity of coronary stenosis in the Women's Ischemia Syndrome Evaluation study. J Lipid Res. 2011;52(4):801-7. [
DOI:10.1194/jlr.M012963] [
PMID] [
PMCID]
37. Cipollini M, Landi S, Gemignani F. MicroRNA binding site polymorphisms as biomarkers in cancer management and research. Pharmgenomics Pers Med. 2014;7:173-91. [
DOI:10.2147/PGPM.S61693] [
PMID] [
PMCID]